Condition: HFMD · Sponsor: Zhengzhou Children's Hospital, China
This is a multicenter clinical trial investigating the safety and efficacy of inhaled Peginterferon α-2b at different doses, in combination with supportive care, for the treatment of patients with hand, foot, and mouth disease (HFMD) of ordinary type. The trial aims to enroll 90 patients with HFMD. Eligible subjects will be randomly assigned to receive either supportive care + Peginterferon α-2b mcg or supportive care + Peginterferon α-2b 90 mcg, administered on days 1 and 3. The study period includes a 3-day screening phase and a 5-7 day inpatient visit period. The results of this trial will be used to evaluate safety and efficacy.
This description comes directly from the study's public registry record.
Fang Wang · 13783637576 · 13783637576@139.com
Always discuss trial participation with your own doctor first.
| Xindu District People's Hospital of Chengdu | Chengdu, China | Recruiting |
| The Seventh People's Hospital of Liangshan Yi Autonomous Prefecture | Liangshan, China | Recruiting |
| Henan Children's Hospital (Zhengzhou Children's Hospital) | Zhengzhou, China | Recruiting |
| Zhengzhou People's Hospital | Zhengzhou, China | Recruiting |
| Ziyang Central Hospital | Ziyang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07008755